Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial

Dose-Dependent Effects of Aficamten Compared With Metoprolol in Obstructive HCM: The MAPLE-HCM Study

Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients

Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM Long-Term Study

The Effect of Aficamten vs Metoprolol on Cardiac Biomarkers in Obstructive Hypertrophic Cardiomyopathy: A Secondary Analysis From MAPLE-HCM

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial

Clinical Responses to Aficamten Monotherapy Compared with Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis

Effects of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive HCM

Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy